Soy isoflavones and fatty acids: Effects on bone tissue postovariectomy in mice

Molecular Nutrition and Food Research

Volumn 51, Issue 7, 2007, Pages 824-831

  Ward, Wendy E ^a   Fonseca, Debbie ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Biomechanical bone strength; Bone mineral density; Fish oil; Isoflavones; Mice

Indexed keywords

FATTY ACID; ISOFLAVONE DERIVATIVE; OMEGA 3 FATTY ACID; OSTEOCALCIN;

ANIMAL; ARTICLE; BIOMECHANICS; BLOOD; BONE; BONE DENSITY; CHEMISTRY; DRUG EFFECT; FEMALE; FEMUR; LUMBAR VERTEBRA; MOUSE; OVARIECTOMY; PHYSIOLOGY; SOYBEAN;

ANIMALS; BIOMECHANICS; BONE AND BONES; BONE DENSITY; FATTY ACIDS; FATTY ACIDS, OMEGA-3; FEMALE; FEMUR; ISOFLAVONES; LUMBAR VERTEBRAE; MICE; OSTEOCALCIN; OVARIECTOMY; SOYBEANS;

MUS;

EID: 34547415141     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.200600187     Document Type: Article

References (41)

1. U.S. Surgeon General, U.S. Surgeon General's Report on Bone Health, U.S. Department of Health and Human Services, Rockville, MD, USA, 2004, pp. 1-371.
2. Reginster, J. Y., Burlet, N., Osteoporosis: A still increasing prevalence, Bone 2006, 38, S4-S9.
3. Riggs, B. L., Melton, L. J., III, The worldwide problem of osteoporosis: Insights afforded by epidemiology, Bone 1995, 17, 505S-511S.
4. Morales-Torres, J., Gutierrez-Urena, S., The burden of osteoporosis in Latin America, Osteoporos Int. 2004, 15, 625-632.
5. Brown, J. P., Josse, R. G., 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada, CMAJ 2002, 167, S1-S34.
6. Papadimitropoulos, E. A., Coyte, P. C., Josse, R. G., Greenwood, C. E., Current and projected rates of hip fracture in Canada, CMAJ 1997,157, 1357-1363.
7. Reinwald, S., Weaver, C. M., Soy isoflavones and bone health: A double-edged sword?, J. Nat. Prod. 2006, 69, 450-459.
8. Weaver, C. M., Cheong, J. M., Soy isoflavones and bone health: The relationship is still unclear, J. Nutr. 2005, 135, 1243-1247.
9. Breitman, P. L. et al., Isoflavones with supplemental calcium provide greater protection against the loss of bone mass and strength after ovariectomy compared to isoflavones alone, Bone 2003, 33, 597-605.
10. Breitman, P. L., Fonseca, D., Ward, W. E., Combination of soy protein and high dietary calcium on bone biomechanics and bone mineral density in ovariectomized rats, Menopause 2005, 12, 428-435.
11. Fonseca, D., Ward, W. E., Daidzein together with high calcium preserve bone mass and biomechanical strength at multiple sites in ovariectomized mice, Bone 2004, 35, 489-497.
12. Setchell, K. D., Soy isoflavones-benefits and risks from nature's selective estrogen receptor modulators (SERMs), J. Am. Coll. Nutr. 2001, 20, 354S-362S; discussion 381S-383S.
13. James, M. J., Gibson, R. A., Cleland, L. G., Dietary polyunsaturated fatty acids and inflammatory mediator production, Am. J. Clin. Nutr. 2000, 71, 343S-348S.
14. Watkins, B. A. et al., Modulatory effect of omega-3 polyunsaturated fatty acids on osteoblast function and bone metabolism, Prostaglandins Leukot Essent Fatty Acids 2003, 68, 387-398.
15. Watkins, B. A., Li, Y., Seifert, M. F., Dietary ratio of n-6/n-3 PUFAs and docosahexaenoic acid: Actions on bone mineral and serum biomarkers in ovariectomized rats, J. Nutr. Biochem. 2006, 17, 282-289.
16. Haag, M., et al., Omega-3 fatty acids modulate ATPases involved in duodenal Ca absorption, Prostaglandins Leukot Essent Fatty Acids 2003, 68, 423-429.
17. Watkins, B. A., et al., Protective actions of soy isoflavones and n-3 PUFAs on bone mass in ovariectomized rats, J. Nutr. Biochem. 2005, 16, 479-488.
18. Canadian Council on Animal Care, Guide to the Care and Use of Experimental Animals, Canadian Council on Animal Care, Ottawa, Ontario, Canada 1993, p. 1-211.
19. Jochems, C., et al., Osteoporosis in experimental postmenopausal polyarthritis: The relative contributions of estrogen deficiency and inflammation, Arthritis Res. Ther. 2005, 7, R837-R843.
20. Verdrengh, M., et al., Addition of bisphosphonate to antibiotic and anti-inflammatory treatment reduces bone resorption in experimental Staphylococcus aureus-induced arthritis, J. Orthop. Res. 2007, 25, 304-310.
21. Ohta, A., et al., A combination of dietary fructooligosaccharides and isoflavone conjugates increases femoral bone mineral density and equol production in ovariectomized mice, J. Nutr. 2002, 132, 2048-2054.
22. Picherit, C., et al., Daidzein is more efficient than genistein in preventing ovariectomy-induced bone loss in rats, J. Nutr. 2000, 130, 1675-1681.
23. Fujioka, M., et al., Equol, a metabolite of daidzein, inhibits bone loss in ovariectomized mice, J. Nutr. 2004, 134, 2623-2627.
24. Ward, W. E., et al., Serum equol, bone mineral density and biomechanical bone strength differ among four mouse strains, Nutr. Biochem. 2005, 16, 743-749.
25. Jia, T. L., et al., Daidzein enhances osteoblast growth that may be mediated by increased bone morphogenetic protein (BMP) production, Biochem. Pharmacol. 2003, 65, 709-715.
26. Sliwinski, L., et al., Differential effects of genistein, estradiol and raloxifene on rat osteoclasts in vitro, Pharmacol. Rep. 2005, 57, 352-359.
27. Gao, Y. H., Yamaguchi, M., Suppressive effect of genistein on rat bone osteoclasts: Involvement of protein kinase inhibition and protein tyrosine phosphatase activation, Int. J. Mol. Med. 2000, 5, 261-267.
28. Chen, W. F., Wong, M. S., Genistein modulates the effects of parathyroid hormone in human osteoblastic SaOS-2 cells, Br. J. Nutr. 2006, 95, 1039-1047.
29. Weitzmann, M. N., Pacifici, R., Estrogen regulation of immune cell bone interactions, Ann. N Y Acad. Sci. 2006, 1068, 256-274.
30. Weitzmann, M. N., Pacifici, R., Estrogendeficiency and bone loss: An inflammatory tale, J. Clin. Invest. 2006, 116, 1186-1194.
31. Cohen, S. L., Moore, A. M., Ward, W. E., Interleukin-10 knockout mouse: A model for studying bone metabolism during intestinal inflammation, Inflamm. Bowel. Dis. 2004, 10, 557-563.
32. Ly, L. H., et al., Dietary n-3 polyunsaturated fatty acids suppress splenic CD4(+) T cell function in interleukin (IL)-10(-/-) mice, Clin. Exp. Immunol. 2005, 139, 202-209.
33. Arrington, J. L., et al., Dietary n-3 polyunsaturated fatty acids modulate purified murine T-cell subset activation. Clin. Exp. Immunol. 2001, 125, 499-507.
34. Arjmandi, B. H., et al., Bone-sparing effect of soy protein in ovarian hormone-deficient rats is related to its isoflavone content, Am. J. Clin. Nutr. 1998, 68, 1364S-1368S.
35. Arjmandi, B. H., et al., Role of soy protein with normal or reduced isoflavone content in reversing bone loss induced by ovarian hormone deficiency in rats, Am. J. Clin. Nutr. 1998, 68, 1358S-1363S.
36. Harrison, E., et al., The effect of soybean protein on bone loss in a rat model of postmenopausal osteoporosis, J. Nutr. Sci. Vitaminol. (Tokyo) 1998, 44, 257-268.
37. Ishida, H., et al., Preventive effects of the plant isoflavones, daidzin and genistin, on bone loss in ovariectomized rats fed a calcium-deficient diet, Biol. Pharm. Bull. 1998, 21, 62-66.
38. Cai, D. J., et al., Comparative effect of soy protein, soy isoflavones, and 17beta-estradiol on bone metabolism in adult ovariectomized rats, J. Bone Miner. Res. 2005, 20, 828-839.
39. Felsenberg, D., Boonen, S., The bone quality framework: Determinants of bone strength and their interrelationships, and implications for osteoporosis management, Clin. Ther. 2005, 27, 1-11.
40. Rubin, C. D., Emerging concepts in osteoporosis and bone strength, Curr. Med. Res. Opin. 2005, 21, 1049-1056.
41. Kruger, M. C., Scholium, L. M., Is docosahexaenoic acid more effective than eicosapentaenoic acid for increasing calcium bioavailability? Prostaglandins Leukot Essent Fatty Acids 2005, 73, 327-334.